Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment
NCT01473043
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
- Metastatic renal cell carcinoma with a component of clear cell subtype.
- Prior first line systemic therapy
- At least 1 measurable lesion as per Response Evaluation Criterion in Solid Tumors [RECIST 1.1].
- Adequate hematology, liver and kidney functions
- Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1.
- Life expectancy of ≥12 weeks.
- Normotensive or well controlled hypertension (less than/equal to 140/90 mm Hg.)
- Negative pregnancy test
- Adequate recovery time from prior systemic therapy, surgery or radiation
- Willing and able subjects who have signed consent
- More than one prior systemic therapy regimen
- Major bowel-penetrating surgery <4 weeks
- Active gastro intestinal bleed in past 3 months
- Active peptic ulcer disease in the past 6 months
- Current or anticipated use of potent CYP3A4/5 inhibitors
- Current or anticipated use of known CYP3A4/5 or CYP1A2 inducers
- Requirement for therapeutic warfarin or high dose steroids
- Symptomatic or untreated brain metastases
- A serious uncontrolled medical disorder or active infection
- Pregnant or breastfeeding females
- History of another active malignancy
- Dementia
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- New York, New York
- Toronto, Ontario
- Durham, North Carolina
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment | |||
| Brief Summary | This is a single arm study with axitinib in patients with advanced kidney cancer (clear cell variant), who have failed first line therapy. The study will recruit a maximum of 30 patients from 2 countries including Australia and Canada. Patients will be followed up for efficacy, safety and health related outcomes. | |||
| Detailed Description | Not Provided | |||
| Study Type | Expanded Access | |||
| Intervention | Drug: Axitinib
5mg twice daily [BD] daily dosing until progression or prohibitive toxicity Dose titration by 2 levels upwards (7mg and 10mg) and downwards (3mg and 2mg) allowed per protocol Other Name: AG-013736 | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Expanded Access Status | No longer available | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Australia, Canada | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT01473043 | |||
| Responsible Party | Pfizer | |||
| Study Sponsor | Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Pfizer | |||
| Verification Date | May 2014 | |||